Browse PLEKHG6

Summary
SymbolPLEKHG6
Namepleckstrin homology domain containing, family G (with RhoGef domain) member 6
Aliases FLJ10665; MYOGEF; myosin II interacting GEF; PH domain-containing family G member 6; myosin interacting guan ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell projection, microvillus Cytoplasm, cytoskeleton, spindle Cytoplasm, cytoskeleton, spindle pole Cleavage furrow Note=During mitosis, localizes to the spindle pole, central spindle and cleavage furrow (PubMed:16721066). In epithelial cells, recruited to the apical membrane by EZR where it participates in macropinocytosis (PubMed:17881735).
Domain PF00621 RhoGEF domain
Function

Guanine nucleotide exchange factor activating the small GTPase RHOA, which, in turn, induces myosin filament formation. Also activates RHOG. Does not activate RAC1, or to a much lower extent than RHOA and RHOG. Part of a functional unit, involving PLEKHG6, MYH10 and RHOA, at the cleavage furrow to advance furrow ingression during cytokinesis. In epithelial cells, required for the formation of microvilli and membrane ruffles on the apical pole. Along with EZR, required for normal macropinocytosis.

> Gene Ontology
 
Biological Process GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0035023 regulation of Rho protein signal transduction
GO:0046578 regulation of Ras protein signal transduction
GO:0051056 regulation of small GTPase mediated signal transduction
Molecular Function GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005089 Rho guanyl-nucleotide exchange factor activity
GO:0005096 GTPase activator activity
GO:0008047 enzyme activator activity
GO:0030695 GTPase regulator activity
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0000922 spindle pole
GO:0005819 spindle
GO:0005902 microvillus
GO:0032153 cell division site
GO:0032154 cleavage furrow
GO:0032155 cell division site part
GO:0097610 cell surface furrow
GO:0098858 actin-based cell projection
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolPLEKHG6
Namepleckstrin homology domain containing, family G (with RhoGef domain) member 6
Aliases FLJ10665; MYOGEF; myosin II interacting GEF; PH domain-containing family G member 6; myosin interacting guan ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PLEKHG6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPLEKHG6
Namepleckstrin homology domain containing, family G (with RhoGef domain) member 6
Aliases FLJ10665; MYOGEF; myosin II interacting GEF; PH domain-containing family G member 6; myosin interacting guan ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PLEKHG6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPLEKHG6
Namepleckstrin homology domain containing, family G (with RhoGef domain) member 6
Aliases FLJ10665; MYOGEF; myosin II interacting GEF; PH domain-containing family G member 6; myosin interacting guan ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PLEKHG6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2360.375
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1740.725
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5430.251
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91600.999
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0040.999
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0040.999
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5130.441
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.4750.153
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4760.679
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.6110.0259
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6280.531
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3530.0807
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PLEKHG6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916018.8-18.80.28
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPLEKHG6
Namepleckstrin homology domain containing, family G (with RhoGef domain) member 6
Aliases FLJ10665; MYOGEF; myosin II interacting GEF; PH domain-containing family G member 6; myosin interacting guan ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLEKHG6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPLEKHG6
Namepleckstrin homology domain containing, family G (with RhoGef domain) member 6
Aliases FLJ10665; MYOGEF; myosin II interacting GEF; PH domain-containing family G member 6; myosin interacting guan ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLEKHG6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLEKHG6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPLEKHG6
Namepleckstrin homology domain containing, family G (with RhoGef domain) member 6
Aliases FLJ10665; MYOGEF; myosin II interacting GEF; PH domain-containing family G member 6; myosin interacting guan ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLEKHG6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPLEKHG6
Namepleckstrin homology domain containing, family G (with RhoGef domain) member 6
Aliases FLJ10665; MYOGEF; myosin II interacting GEF; PH domain-containing family G member 6; myosin interacting guan ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PLEKHG6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPLEKHG6
Namepleckstrin homology domain containing, family G (with RhoGef domain) member 6
Aliases FLJ10665; MYOGEF; myosin II interacting GEF; PH domain-containing family G member 6; myosin interacting guan ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PLEKHG6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPLEKHG6
Namepleckstrin homology domain containing, family G (with RhoGef domain) member 6
Aliases FLJ10665; MYOGEF; myosin II interacting GEF; PH domain-containing family G member 6; myosin interacting guan ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PLEKHG6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.